Summary
16.52 -0.06(-0.33%)09/16/2024
Hims & Hers Health Inc (HIMS)
Hims & Hers Health Inc (HIMS)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -0.33 | 9.64 | -0.94 | -33.36 | 7.95 | 144.74 | 0.00 | 61.33 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 16.52 | |
| Open | 16.45 | |
| High | 16.62 | |
| Low | 16.14 | |
| Volume | 739,615 | |
| Change | -0.06 | |
| Change % | -0.33 | |
| Avg Volume (20 Days) | 6,376,623 | |
| Volume/Avg Volume (20 Days) Ratio | 0.12 | |
| 52 Week Range | 0.00 - 25.74 | |
| Price vs 52 Week High | -35.84% | |
| Price vs 52 Week Low | inf% | |
| Range | 3.74 | |
| Gap Up/Down | -0.26 | |
Fundamentals | ||
| Market Capitalization (Mln) | 3,448 | |
| EBIDTA | 0 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 11.20 | |
| Book Value | 1.7430 | |
| Earnings Per Share | -0.4350 | |
| EPS Estimate Current Quarter | -0.0600 | |
| EPS Estimate Next Quarter | -0.0600 | |
| EPS Estimate Current Year | -0.3800 | |
| EPS Estimate Next Year | -0.1500 | |
| Diluted EPS (TTM) | -0.4350 | |
| Revenues | ||
| Profit Marging | -0.3574 | |
| Operating Marging (TTM) | -0.3751 | |
| Return on asset (TTM) | -0.1988 | |
| Return on equity (TTM) | -0.3577 | |
| Revenue TTM | 228,644,992 | |
| Revenue per share TTM | 1.2170 | |
| Quarterly Revenue Growth (YOY) | 0.7950 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | 109,450,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 3.5024 | |
| Revenue Enterprise Value | 25.1922 | |
| EBITDA Enterprise Value | 0.0000 | |
| Shares | ||
| Shares Outstanding | 195,536,000 | |
| Shares Float | 114,542,088 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 18.78 | |
| Institutions (%) | 47.72 | |
09/16 09:32 EST - seekingalpha.com
Hims & Hers: Fear Surrounding GLP-1 Provides Another Opportunity
Hims & Hers' stock decline after GLP-1 concerns is an overreaction, presenting a strong investment opportunity. Management's consistent outperformance and strategic leadership, including key hires, bolster confidence in Hims' ability to scale and achieve ambitious targets. Exceptional revenue growth, healthy balance sheet, and a share buyback program highlights Hims' strong financial position.
Hims & Hers: Fear Surrounding GLP-1 Provides Another Opportunity
Hims & Hers' stock decline after GLP-1 concerns is an overreaction, presenting a strong investment opportunity. Management's consistent outperformance and strategic leadership, including key hires, bolster confidence in Hims' ability to scale and achieve ambitious targets. Exceptional revenue growth, healthy balance sheet, and a share buyback program highlights Hims' strong financial position.
09/13 15:05 EST - fool.com
Hims & Hers Stock Pops After Massive Acquisition
Hims & Hers completed the acquisition of MedisourceRX, a pharmacy that will expand in-house production. The deal included issuing stock, which will ultimately dilute shareholders.
Hims & Hers Stock Pops After Massive Acquisition
Hims & Hers completed the acquisition of MedisourceRX, a pharmacy that will expand in-house production. The deal included issuing stock, which will ultimately dilute shareholders.
09/13 10:05 EST - zacks.com
Hims & Hers Health, Inc. (HIMS) Is a Trending Stock: Facts to Know Before Betting on It
Zacks.com users have recently been watching Hims & Hers Health (HIMS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Hims & Hers Health, Inc. (HIMS) Is a Trending Stock: Facts to Know Before Betting on It
Zacks.com users have recently been watching Hims & Hers Health (HIMS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
09/11 08:50 EST - fool.com
Hims & Hers Health Stock Is Crashing: Should You Buy the Dip?
Hims & Hers' business grew by more than 50% last quarter. The company has plenty more growth opportunities to pursue in pain management, fertility, and diabetes.
Hims & Hers Health Stock Is Crashing: Should You Buy the Dip?
Hims & Hers' business grew by more than 50% last quarter. The company has plenty more growth opportunities to pursue in pain management, fertility, and diabetes.
09/11 07:50 EST - fool.com
Is Hims & Hers Health the Next Teladoc?
Demand for telemedicine services boomed during the pandemic lockdowns. Teladoc stock price soared more than 250%, only to plunge.
Is Hims & Hers Health the Next Teladoc?
Demand for telemedicine services boomed during the pandemic lockdowns. Teladoc stock price soared more than 250%, only to plunge.
09/10 07:31 EST - marketbeat.com
Invest While You Can: Pullbacks on These 3 Stocks Won't Last Long
Traders are often quoted as slaves to volatility, as their entire business model is dependent on stocks moving actively to meet the conditions of a trade and spread. However, long-term value investors are just as dependent on volatility as their distant day-trader counterparts.
Invest While You Can: Pullbacks on These 3 Stocks Won't Last Long
Traders are often quoted as slaves to volatility, as their entire business model is dependent on stocks moving actively to meet the conditions of a trade and spread. However, long-term value investors are just as dependent on volatility as their distant day-trader counterparts.
09/10 04:20 EST - fool.com
Is Hims & Hers Health Stock a Buy?
Hims & Hers stock price has plummeted in recent weeks. Share prices no longer reflect GLP-1 hype.
Is Hims & Hers Health Stock a Buy?
Hims & Hers stock price has plummeted in recent weeks. Share prices no longer reflect GLP-1 hype.
09/05 13:06 EST - zacks.com
Hims & Hers Stock Plunges 32.1% in Three Months: What's Next?
HIMS is enhancing its offerings and expanding the breadth of health and wellness products and services. However, macro challenges are likely to hurt its performance.
Hims & Hers Stock Plunges 32.1% in Three Months: What's Next?
HIMS is enhancing its offerings and expanding the breadth of health and wellness products and services. However, macro challenges are likely to hurt its performance.
09/05 04:50 EST - fool.com
Got $1,000? 3 Healthcare Stocks to Buy and Hold Forever
Hims & Hers is rapidly picking up steam in the telehealth industry. UnitedHealth's dominance has created massive wealth for long-term investors.
Got $1,000? 3 Healthcare Stocks to Buy and Hold Forever
Hims & Hers is rapidly picking up steam in the telehealth industry. UnitedHealth's dominance has created massive wealth for long-term investors.
09/04 13:26 EST - youtube.com
The Big 3: HIMS, TLT & WFC
Ben Lichtenstein and Don Kaufman focus on finance and health in today's Big 3. They break down the technical trends for Hims & Hers (HIMS), the iShares 20+ Year Treasury Bond (TLT), and Wells Fargo (WFC).
The Big 3: HIMS, TLT & WFC
Ben Lichtenstein and Don Kaufman focus on finance and health in today's Big 3. They break down the technical trends for Hims & Hers (HIMS), the iShares 20+ Year Treasury Bond (TLT), and Wells Fargo (WFC).
09/03 16:37 EST - 247wallst.com
Has Eli Lilly Destroyed Hims & Hers Upside?
Capitalizing on the popularity of weight-loss drugs like Wegovy and Zepbound, Hims & Hers Health (NYSE:HIMS) has exploited a loophole in Food & Drug Administration regulations to bring to market similar drugs without having to undergo the rigors of clinical testing the pharmaceutical giants are required to pursue.
Has Eli Lilly Destroyed Hims & Hers Upside?
Capitalizing on the popularity of weight-loss drugs like Wegovy and Zepbound, Hims & Hers Health (NYSE:HIMS) has exploited a loophole in Food & Drug Administration regulations to bring to market similar drugs without having to undergo the rigors of clinical testing the pharmaceutical giants are required to pursue.
09/02 10:01 EST - zacks.com
Investors Heavily Search Hims & Hers Health, Inc. (HIMS): Here is What You Need to Know
Recently, Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine what the stock has in store.
Investors Heavily Search Hims & Hers Health, Inc. (HIMS): Here is What You Need to Know
Recently, Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine what the stock has in store.
09/01 03:57 EST - fool.com
Billionaires Are Buying Hims & Hers Health Hand Over Fist. Should You Follow Their Lead?
Funds run by Israel Englander, John Overdeck, and David Siegel bought more than a million shares of Hims & Hers Health in the second quarter. Hims & Hers Health runs a niche telehealth service for people who don't want to ask their regular physician for drugs that carry a lot of social stigma.
Billionaires Are Buying Hims & Hers Health Hand Over Fist. Should You Follow Their Lead?
Funds run by Israel Englander, John Overdeck, and David Siegel bought more than a million shares of Hims & Hers Health in the second quarter. Hims & Hers Health runs a niche telehealth service for people who don't want to ask their regular physician for drugs that carry a lot of social stigma.
08/31 16:15 EST - fool.com
2 No-Brainer Growth Stocks to Buy With $200 Right Now
Both companies revolve around subscription-based services. Hims & Hers is witnessing high-double-digit growth, and profits are soaring.
2 No-Brainer Growth Stocks to Buy With $200 Right Now
Both companies revolve around subscription-based services. Hims & Hers is witnessing high-double-digit growth, and profits are soaring.
08/29 21:52 EST - fool.com
Why Hims & Hers Health Stock Was Falling This Week
Eli Lilly is discounting Zepbound, potentially undercutting a growing business for Hims & Hers. Pharma companies are starting to sell more drugs direct-to-consumer, threatening traditional pharmacies.
Why Hims & Hers Health Stock Was Falling This Week
Eli Lilly is discounting Zepbound, potentially undercutting a growing business for Hims & Hers. Pharma companies are starting to sell more drugs direct-to-consumer, threatening traditional pharmacies.
08/27 16:45 EST - fool.com
Why Hims & Hers Stock Crashed on Tuesday
Eli Lilly's Zepbound got a 50% price cut that could take some of Hims & Hers growth potential. Lower-cost drugs could be good news for Hims & Hers long term.
Why Hims & Hers Stock Crashed on Tuesday
Eli Lilly's Zepbound got a 50% price cut that could take some of Hims & Hers growth potential. Lower-cost drugs could be good news for Hims & Hers long term.
08/27 12:21 EST - investopedia.com
Hims & Hers Health Stock Takes Hit as Eli Lilly Offers Cheaper Weight-Loss Drug
Shares of Hims & Hers Health (HIMS) sank in intraday trading Tuesday on new competition for lower-priced weight-loss drugs from Eli Lilly (LLY).
Hims & Hers Health Stock Takes Hit as Eli Lilly Offers Cheaper Weight-Loss Drug
Shares of Hims & Hers Health (HIMS) sank in intraday trading Tuesday on new competition for lower-priced weight-loss drugs from Eli Lilly (LLY).
08/27 08:44 EST - barrons.com
Eli Lilly Is Offering a Cheaper Form of Zepbound. What It Means for Hims & Hers Stock.
The new option is priced at a 50% or more discount compared to other weight-loss drugs.
Eli Lilly Is Offering a Cheaper Form of Zepbound. What It Means for Hims & Hers Stock.
The new option is priced at a 50% or more discount compared to other weight-loss drugs.
08/22 11:54 EST - fool.com
What Is Going On With Hims & Hers Stock?
After a strong start to the year, the stock is down 30% since June.
What Is Going On With Hims & Hers Stock?
After a strong start to the year, the stock is down 30% since June.